AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02930525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Flow nasal cannula
Description: Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
Study NCT02930525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard respiratory care
Description: Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
Study NCT03769597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol Inj 300 MG/ML
Description: After injecting a loading dose of 5ml of iohexol bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
Study NCT04148963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine
Description: Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
Study NCT04148963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled placebo, may repeat x 1 or 2 after 2 hours
Study NCT01366300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine infusion
Description: Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
Study NCT01366300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% saline infusion)
Description: Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
Study NCT01366300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol 1% (intravenous infusion)
Description: Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
Study NCT01366300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1% (intravenous infusion)
Description: Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
Study NCT01366300 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placement of arterial line
Description: An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
Study NCT01366300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of arterial line
Description: An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
Study NCT02149095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon PEG treprostinil
Study NCT04437472 — intervention group
Intervention type: OTHER
Intervention: CareSignal
Description: The CareSignal software will be programmed to automatically ask a subset of the NCI-PRO-CTCAE questions using SMS depending on patient group as designated by the treating physician: (1) thoracic radiation with chemotherapy, (2) thoracic radiation alone, (3) extremity/body wall sarcoma, and (4) other.
Study NCT04322786 — intervention group
Intervention type: DRUG
Intervention: ACE inhibitor
Description: Any prescription of ACE inhibitor
Study NCT00850096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Nasulin
Description: Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
Study NCT00850096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasulin
Description: Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
Study NCT04499105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell + NaCl 0,9% 2ml
Description: Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.
Study NCT01880567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT01880567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01880567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03938649 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional IMRT
Description: RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
Study NCT03938649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT
Description: RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
Study NCT04337060 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Single-injection ultrasound-guided bilateral erector spinae plane (ESP) block-Sham
Description: With the patient in the sitting position, 20 ml normal saline will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: after anesthesia induction, paracetamol 1 gr intravenous (IV)+ tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV morphine patient-controlled analgesia (PCA) of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit).
Study NCT04668170 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood collection on admission and longitudinally
Description: Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
Study NCT04668170 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood collection on their first consultation and 10 to 14 days later
Description: Samples already collected on consultation (D0) and 14 days later
Study NCT02844907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
Study NCT02844907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
Study NCT02844907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemic Clamp
Description: A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
Study NCT02143830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.
Study NCT02143830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
Study NCT02143830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
Study NCT02143830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit ATG
Description: Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
Study NCT02143830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: All patients will also receive G-CSF post-transplant to foster engraftment.
Study NCT02143830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell
Description: The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
Study NCT00044707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide acetate
Description: Clear, colorless, sterile solution for SC injection.
Study NCT01075906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine sprinkle capsules
Description: 0.3 mg
Study NCT03325894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465
Description: SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.
Study NCT01823172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Methylene blue dye injection of sentinel lymph node
Description: Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
Study NCT03398863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cleaning of uterine cavity
Description: Procedure: Cleaning the uterine cavity These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
Study NCT03244618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSSP Toothpaste
Description: Toothpaste containing calcium silicate, sodium phosphate and sodium monofluorophosphate
Study NCT03244618 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride Toothpaste
Description: Toothpaste containing sodium monofluorphosphate
Study NCT03950141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and S-1
Description: Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
Study NCT00757029 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: norepinephrine transporter polymorphism,
Description: OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
Study NCT02574702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application of a contralateral drainage (Penrose ® device)
Description: application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
Study NCT02613715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackberry juice with 12% ethanol
Study NCT02613715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackberry juice
Study NCT05260775 — intervention group
Intervention type: OTHER
Intervention: Evaluation test: cataract surgery steps
Description: The development datasets were used to train the deep learning model. The validation and test group were used to optimize hyperparameters
Study NCT02727426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Salt (LS) diet
Description: Intake of less than 2.3 g of salt per day for 7 days.
Study NCT02727426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Salt (HS) diet
Description: Intake of 11.2 g of salt per day for 7 days.
Study NCT03715231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIDEK Gonioscope GS-1
Description: To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
Study NCT03715231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Digital Gonioscopic Images
Description: To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
Study NCT02933905 — intervention group
Intervention type: DRUG
Intervention: Intravitreal Ranibizumab injection
Study NCT00555126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced Air Warming
Description: Warming after Randomization
Study NCT04337060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection ultrasound-guided bilateral erector spinae plane block-Lidocaine/Bupivacaine
Description: With the patient in the sitting position, 10 ml 1% lidocaine + 10 ml 0.5% bupivacaine will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: After anesthesia induction, paracetamol 1 gr IV + tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV PCA of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit).
Study NCT04337060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain follow-up and monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 15th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours with two different conditions which are at rest and while couching.If NRS score becomes ≥4 Dexketoprofen 50 mg will be administered (max 4 times).
Study NCT04337060 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain follow-up and monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 15th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours with two different conditions which are at rest and while couching.If NRS score becomes ≥4 Dexketoprofen 50 mg will be administered (max 4 times).
Study NCT01927692 — intervention group
Intervention type: OTHER
Intervention: Skin biopsy
Description: An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
Study NCT01927692 — intervention group
Intervention type: OTHER
Intervention: Single Fiber Electromyography
Description: An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
Study NCT04315623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation CRRT
Description: Regional citrate anticoagulation Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
Study NCT04315623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No-anticoagulation CRRT
Description: Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
Study NCT03119610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
Study NCT03119610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
Study NCT00071240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin (recombinant human growth hormone)
Description: 3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
Study NCT00071240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin (recombinant human growth hormone)
Description: 3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
Study NCT02864043 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NvisionVLE with Real Time Targeting
Description: Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
Study NCT02864043 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: esophagogastroduodenoscopy (EGD)
Description: Standard of care EGD
Study NCT02223065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Study NCT02223065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Study NCT02460081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDA-002
Study NCT02460081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01643746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supera Stent
Description: Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
Study NCT01643746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Life Stent
Description: Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
Study NCT01193543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calanus oil
Description: 1 gram twice daily
Study NCT01193543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: 1 gram twice daily
Study NCT03702101 — intervention group
Intervention type: DEVICE
Intervention: Auricular point detector
Description: This device is only for auricular detection. No additional intervention will be delivered.
Study NCT00555126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warming with endovascular catheter + forced air warming
Description: Warming after Randomization
Study NCT00696202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena (BAY86-5028)
Description: Intrauterine levonorgestrel containing device (market product)
Study NCT03568032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of intima media thickness of carotid artery
Description: IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.
Study NCT03568032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection and measurement of carotid plaques
Description: Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound
Study NCT03568032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid Color Flow Duplex Testing
Description: Velocity measurement of carotid artery to determine carotid stenosis
Study NCT03568032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: Cognitive assessment
Study NCT03568032 — intervention group
Intervention type: OTHER
Intervention: Medical history of cardiovascular risk factors and cardiovascular diseases
Description: Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
Study NCT03534115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAC
Description: solution containing NAC
Study NCT03534115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04056000 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200 mg of caffeine, 60 minutes before exercise